Alexandra Wald

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

Jürgen Behr, Antje Prasse, Michael Kreuter et al. · The Lancet Respiratory Medicine · 2021 · 516 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +9

Factors Associated with Worse Lung Function in Cystic Fibrosis Patients with Persistent Staphylococcus aureus

Sibylle Junge, Dennis Görlich, M den Reijer et al. · PLoS ONE · 2016 · 75 citations · Full text

Veterinary Medicine, Infectious Diseases, Medical Microbiology +16

Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry

Sivagurunathan Sutharsan, Stefanie Dillenhoefer, Matthias Welsner et al. · The Lancet Regional Health - Europe · 2023 · 70 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +14

Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study

Nikolaus Kneidinger, Matthias Hecker, Vasiliki Bessa et al. · Infection · 2022 · 27 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity

Sophie Steiner, Tatjana Schwarz, Victor M. Corman et al. · Frontiers in Immunology · 2022 · 26 citations · Full text

Life Sciences, Immunology, Infectious Diseases +16